NR4A1 and cancer: Although the use of CDK4/6 inhibitors has improved PFS in patients with hormone receptor-positive, HER2−breast cancer, studies have shown that resistance pathways can lead cells to be insensitive to CDK4/6 inhibitors, leading to continued cell proliferation [27,28].